Boston Therapeutics — Investor Presentation (June 2018)
18 slides from Boston Therapeutics's investor presentation, Jun 1, 2018
Slide 1: Transforming Metabolic Diseases
TRANSFORMING METABOLIC DISEASES CARL W. RAUSCH, CEO | LORAINE V. UPHAM, COO June 2018 Confidential and Proprietary 1 OTCQB:BTHE
Slide 2: Boston Therapeutics: Who We Are
Boston Therapeutics We are a BioPharmaceutical company with technology and treatments to prevent or reverse diabetes and its complications. WHO WE ARE Confidential and Proprietary 2 GLYCO CHEMISTRY BTI - 320 SUGARDOWN ® PEPTIDE CHEMISTRY BTI - 410
Slide 3: Safe Harbor Statement
Safe Harbor Statement Confidential and Proprietary 3 This presentation includes forward - looking statements . These statements may be identified by words such as "feel," "believes," expects," "estimates," "projects," "intends," "should," "is to be," or the negative of such terms, or other comparabl
Slide 4: A Global Presence
A Global Presence Confidential and Proprietary 4 WHO WE ARE We have operations in both North America and Asia. 2007 BTI Founded 2011 - 2014 ▪ BTI - 320 Phase I Safety Confirmed ▪ HIP2B Phase I Safety Confirmed 2015 - 2017 ▪ BTI - 320 POC Study Completed in Prediabetes ▪ HIP2B Phase Ib Study Efficacy
Slide 5: Type 2 Diabetes – A Worldwide Reality
Type 2 Diabetes (T2DM) – A Worldwide Reality Source: IDF Diabetes Atlas 7 th Edition, 2015 Confidential and Proprietary 5 WHY DO WE EXIST? In addition to the 425 million adults who are estimated to currently have diabetes, there are 318 million adults with impaired glucose tolerance, which puts them
Slide 6: Addressable Market
425 MILLION 318 MILLION ADULTS ESTIMATED TO HAVE DIABETES ADULTS WITH IMPAIRED GLUCOSE TOLERANCE The number of people with diabetes is projected to increase to 629 Million by 2045. Type 2 Diabetes Global Market is set to Almost Double Confidential and Proprietary 6 ADDRESSABLE MARKET $64B USD 2025 E
Slide 7: New Approaches: Adding Innovation to Current Treatments
GENERATES NEW INSULIN PRODUCING CELLS WRINGS INSULIN OUT OF EXISTING CELLS DECREASES HEPATIC GLUCOSE PRODUCTION INCREASES INSULIN SENSITIVITY BLOCKS REABSORPTION BY THE KIDNEY INCREASES SATIETY BLOCKS ABSORPTION OF SUGAR IN THE GUT New Approaches: Adding Innovation to Current Treatments Confidential
Slide 8: Prediabetes and Type 2 Diabetes – Eliminating Postprandial Spikes
Prediabetes and Type 2 Diabetes – Eliminating Post - prandial spikes Source: CDC Data 2014 Confidential and Proprietary 8 ADDRESSABLE MARKET Prediabetes is defined as: ▪ HbA1c ≥ 5.7 ▪ BMI ▪ Age ▪ Cholesterol? BTI - 320 eliminates postprandial spikes that occur with almost every meal in prediabetes p
Slide 9: SUGARDOWN Mechanism of Action
WITHOUT BTI - 320 STARCH ENZYME Enzymes break down starch into simple sugars (glucose) BTI - 320 WITH BTI - 320 BTI - 320 inhibits enzymes that release glucose from complex carbs STARCH ENZYME BLOOD STREAM BTI - 320 & SUGARDOWN ® Mechanism of Action Confidential and Proprietary 9 OUR PRODUCTS GLUCOS
Slide 10: Mechanism of Action
WITHOUT BTI - 410 Existing islets are diminished in number and have little to no insulin in reserve ready to release. Existing islets are too few in number and have insufficient insulin response to glucose needs and blood sugar gets out of control. WITH BTI - 410 BTI - 410 triggers the maturation of
Slide 11: Our Opportunity
BTI - 410 REVERSES THE PROGRESSION OF T2DM Aids maturation of new insulin secreting cells to avoid ever needing insulin injections. No other treatments can reverse disease progression* Only BTI - 320 is being developed help to prevent diabetes. BTI - 320 STAVES OFF THE START OF T2DM Minimizes postpr
Slide 12: A Clinical Stage Biotech Company
Confidential and Proprietary A Clinical Stage Biotech Company TO GET THERE Developing Therapies that change the course of diabetes. 12 BTI - 320 The 1 st in new class of carbohydrate hydrolyzing enzyme inhibitors 2018 JUN - DEC Phase II Rolling Enrollment of Type 2 diabetes Patients 2019 JUN Study C
Slide 13: BTI Portfolio
BTI Portfolio Confidential and Proprietary 13 TO GET THERE ACCELERATING PIVOTAL BTI - 320 AND BTI - 410 STUDIES LATE STAGE CLINICAL CANDIDATES Efficacy confirmed in Phase 1b/2a Study w/clear safety profile EFFICIENT / VALUE ADD BUSINESS MODEL Addressing metabolic diseases by novel mechanisms and cre
Slide 14: Development Plans
Development Plans Confidential and Proprietary 14 TO GET THERE Execute marketing plan for SUGARDOWN ® in Asia and US Complete BTI - 320 Phase II Study in Type 2 Diabetes in collaboration with the Joslin Diabetes Center Complete Phase II Clinical Trial in Renal Transplant Patients ▪ Enroll 36 patient
Slide 15: Proposed STEPS Study
Proposed BTI - 320 STEPS Study Confidential and Proprietary 15 TO GET THERE STEPS: SUGARDOWN ® TO ELIMINATE POSTPRANDIAL SPIKES Type 2 diabetes Adults 18 - 70 TID Chewable Tablets; 4g and 8g doses 27 Weeks Treatment Monitored 3 days with CGM, 5 times N = 60 2:2:1 design Blinded, Placebo Controlled
Slide 16: Proposed Phase II TRIUMPH and TRINITY Studies
Proposed Phase 2 in T1DM TRIUMPH Study Confidential and Proprietary 16 TO GET THERE N = 36 2:1 design T1DM On multiple daily insulin dosages, tacrolimus and mycophenolate or <5mg / day Prednisone Adults 30 - 65 7.0 ≤HbA1c ≤10.0 200 mg BID daily subQ injections 90 days Treatment & Followed out to 180
Slide 17: Revenue Streams
ACTIVE REVENUE SOURCE IN ASIA! Revenue Streams Confidential and Proprietary 17 OUR OPPORTUNITY SUPPLEMENT MARKET BTI - 320 BTI - 410 Provides large safety database Rx for potentially for prediabetes and diabetes Potentially “Curative” for Type 1 diabetes on immunosuppression No Rx needed Non - syste
Slide 18: Questions?
Questions? Confidential and Proprietary 18
Boston Therapeutics — Investor Presentation (June 2018) on 6ix